DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers (DO IT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01419262|
Recruitment Status : Completed
First Posted : August 18, 2011
Last Update Posted : November 17, 2015
Vitamin D can be made in the skin by exposure to sunlight and can be found in certain foods. Vitamin D levels are alarmingly low in many North American children. Several health issues have been linked with low vitamin D. These include colds caused by viruses and asthma attacks. However, no study has determined whether vitamin D supplementation can reduce the risk of these conditions in young children where they are most common and most severe.
The goals of this study are to determine whether wintertime high dose vitamin D supplementation of preschoolers can prevent colds and asthma attacks. The investigators also aim to work out how much money would be saved by the health care system and society if preschoolers were routinely supplemented with Vitamin D during the winter. The investigators believe that preschoolers receiving 'high dose' vitamin D supplementation during the wintertime will be less likely to have colds, asthma attacks, and low vitamin D levels and will be less likely to use the medical system and keep their parents away from work.
|Condition or disease||Intervention/treatment||Phase|
|Respiratory Tract Infections Asthma Avitaminosis||Drug: Vitamin D - Cholecalciferol 400 IU Drug: Vitamin D3 - Cholecalciferol 2000 IU||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||703 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||May 2015|
|Actual Study Completion Date :||October 2015|
|Experimental: 2000 IU per day vitamin D||
Drug: Vitamin D3 - Cholecalciferol 2000 IU
One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Other Name: Ddrops 2000 IU
|Active Comparator: 400 IU per day vitamin D||
Drug: Vitamin D - Cholecalciferol 400 IU
One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
- Number of Laboratory confirmed upper respiratory tract infections [ Time Frame: Up to 8 months ]Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Reverse transcriptase polymerase chain reaction will be performed on each sample. Samples will be tested for 18 common respiratory viruses using the ID-TagTM RVP assay using the Luminex xMAPTM system.
- Number of parent reported upper respiratory tract infections [ Time Frame: Up to 8 months ]Parental reported URTI symptoms will be defined as two or more of fever, cough, runny nose, sore throat, headache, vomiting, feels unwell, muscle aches, ear ache or infection, poor appetite, not sleeping well, cranky/fussy, low energy or crying more than usual from a validated parent completed symptom checklist.
- Number of Asthma exacerbations [ Time Frame: Up to 8 months ]Asthma exacerbation will be defined as a wheezing episode in children with asthma as obtained from parent completed symptom checklist based on the International Study of Asthma and Allergies in Childhood (ISAAC).
- Serum vitamin D level [ Time Frame: 5-8months ]Blood for serum levels will be drawn by trained pediatric phlebotomists from for determination of 25-hydroxyvitamin D. Total 25-hydroxyvitamin D will be measured from serum samples using a competitive two-step chemiluminescence assay.
- Direct and indirect economic costs associated with upper respiratory tract infections [ Time Frame: 16 months ]Cost-consequence and cost-effectiveness analyses will be conducted using data from this clinical trial. A societal perspective will be employed as both direct health service utilization costs as well as indirect costs to families from URTI will be calculated for the 400 IU per day versus 2000 IU per day groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419262
|St. Michael's Hospital|
|Toronto, Ontario, Canada, M5B 1W8|
|Hospital for Sick Children|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Jonathon L Maguire, MD, MSc||St. Michael's Hospital, Toronto, Ontario, Canada|